Source comparison
Stacking Thymosin Alpha-1 LL-37 Immune Research: Protocol Comparison
Acute Sepsis Model 1.6 mg/kg SC 0.8 mg/kg IP Simultaneous, 2h pre-challenge 72h survival rate, bacterial load Best for immediate immune response. 79% survival vs 61% single-agent Chronic Viral Model 0.8 mg/kg SC 0.4 mg/kg SC Sequential: TA1 day 1, LL-37 day 3
This comparison does not assign a generated winner or score.
- Acute Sepsis Model
- 1.6 mg/kg SC
- 0.8 mg/kg IP
- Simultaneous, 2h pre-challenge
- 72h survival rate, bacterial load
- Best for immediate immune response. 79% survival vs 61% single-agent
- Chronic Viral Model
- 0.8 mg/kg SC
- 0.4 mg/kg SC
- Sequential: TA1 day 1, LL-37 day 3
- Viral titer reduction, T-cell count
- Allows T-cell expansion before innate activation. 2.1-fold viral clearance vs control
- In Vitro Neutrophil Function
- 10 µg/mL
- 2.5 µg/mL
- Simultaneous addition to culture
- NET formation, phagocytic capacity
- 3.2-fold NET increase, 42% phagocytosis boost. Mechanistic proof of synergy
- Autoimmune Modulation (Murine EAE)
- 1.0 mg/kg SC, every 48h
- 0.5 mg/kg SC, every 72h
- Staggered: TA1 Mon/Wed/Fri, LL-37 Tue/Fri
- Clinical score reduction, CNS infiltration
- Reduces disease severity by 34% vs single-agent. Balances Treg induction with neutrophil control